Print Page     Close Window     

SEC Filings

10-K
SERES THERAPEUTICS, INC. filed this Form 10-K on 03/16/2017
Entire Document
 

SERES THERAPEUTICS, INC.

CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share data)

 

 

 

December 31,

 

 

 

2016

 

 

2015

 

Assets

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

54,539

 

 

$

73,933

 

Investments

 

 

138,704

 

 

 

131,149

 

Prepaid expenses and other current assets

 

 

5,126

 

 

 

2,528

 

Total current assets

 

 

198,369

 

 

 

207,610

 

Property and equipment, net

 

 

36,125

 

 

 

7,751

 

Long-term investments

 

 

36,752

 

 

 

 

Restricted cash

 

 

1,400

 

 

 

1,539

 

Total assets

 

$

272,646

 

 

$

216,900

 

Liabilities and Stockholder's Equity

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

7,587

 

 

$

5,397

 

Accrued expenses and other current liabilities

 

 

10,812

 

 

 

5,523

 

Deferred revenue - related party

 

 

12,058

 

 

 

 

Total current liabilities

 

 

30,457

 

 

 

10,920

 

Lease incentive obligation, net of current portion

 

 

10,730

 

 

 

586

 

Deferred rent

 

 

2,072

 

 

 

 

Deferred revenue, net of current portion - related party

 

 

96,756

 

 

 

 

Total liabilities

 

 

140,015

 

 

 

11,506

 

Commitments and contingencies

 

 

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

 

 

Preferred stock, $0.001 par value;

    10,000,000 shares authorized at December 31, 2016 and 2015; no shares

    issued and outstanding at December 31, 2016 and 2015

 

 

 

 

 

 

Common stock, $0.001 par value; 200,000,000 shares authorized at December 31, 2016

    and 2015; 40,355,753 and 39,082,017 shares issued and outstanding

    at December 31, 2016 and 2015

 

 

40

 

 

 

39

 

Additional paid-in capital

 

 

306,931

 

 

 

287,937

 

Accumulated other comprehensive income (loss)

 

 

(149

)

 

 

30

 

Accumulated deficit

 

 

(174,191

)

 

 

(82,612

)

Total stockholders’ equity

 

 

132,631

 

 

 

205,394

 

Total liabilities, convertible preferred stock and stockholders’ equity

 

$

272,646

 

 

$

216,900

 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

 

F-3



© Seres Therapeutics. All Rights Reserved.